MTX-474-S101: A Phase 1 Randomized, Double-Blind, Dose-Escalating Study to Assess the Safety, Tolerability, and Pharmacokinetics of MTX-474 in Healthy Adults
Latest Information Update: 09 Aug 2024
At a glance
- Drugs MTX-474 (Primary)
- Indications Fibrosis
- Focus Adverse reactions; First in man; Pharmacokinetics
- Sponsors Mediar Therapeutics
- 07 Aug 2024 According to a Mediar Therapeutics media release, company announced the first cohort of participants has been dosed in a Phase 1 trial evaluating the safety and tolerability of MTX-474.
- 02 Aug 2024 Status changed from planning to recruiting.
- 06 May 2024 According to a Mediar Therapeutics media release, initiation of this Phase 1 study is anticipated in Q3-2024.